GE Healthcare has announced CE marking for SenoClaire, GE’s new generation of breast tomosynthesis solution designed with a three-dimensional imaging technology. SenoClaire technology uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, removing the potential motion from images.

“We are thrilled to receive the CE marking for this important product in our Women’s Health business. We continue to innovate our portfolio and aim to help clinicians expand care to more women globally in order to help reduce breast cancer. Our goal was to pioneer an upgrade solution for both our digital mammography platforms, Senographe* Essential and Senographe Care, providing flexibility for customers to enhance their clinical offering for their clinic and patient workflow,” said Prahlad Singh, General Manager, Women’s Health, GE Healthcare - Detection & Guidance Solutions (DGS).

With GE’s SenoClaire, powered by ASiRDBT a single MLO view provides clinical non-inferiority compared to a 2-view digital mammography exam—at half the dose and with just one compression. 

Source: GE Healthcare, 16 July 2013

«« Ziehm Imaging Launches First Motorised C-arm for Hybrid ORs


PACSGEAR Passes 3,000 Customer Milestone »»



Latest Articles

Tomosynthesis, GE GE Healthcare has announced CE marking for SenoClaire, GE’s new generation of breast tomosynthesis solution designed with a three-dimensional imaging tec...